Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial

Ralph A. Gruppo,Maria‐Fernanda López‐Fernández,Tung Wynn,Werner Engl,Marlies Sharkhawy,Srilatha Tangada

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial

2019

Ralph A. Gruppo
Maria‐Fernanda López‐Fernández
Tung Wynn
Werner Engl
Marlies Sharkhawy
Srilatha Tangada

Introduction Rurioctocog alfa pegol (BAX 855, TAK‐660) is a PEGylated, full‐length, recombinant factor VIII (rFVIII) with extended half‐life developed from unmodified rFVIII (antihaemophilic factor [recombinant]).

Keywords:

Recombinant factor viii
Haemophilia A
Medicine
Surgery
Perioperative
in patient
Half-life
Haemophilia
Adverse effect
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations